IQVIA Holdings Inc. (NYSE:IQV) Position Boosted by JPMorgan Chase & Co.

JPMorgan Chase & Co. grew its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 46.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,845,711 shares of the medical research company's stock after purchasing an additional 583,396 shares during the quarter. JPMorgan Chase & Co. owned approximately 1.02% of IQVIA worth $437,378,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in IQV. Principal Financial Group Inc. lifted its stake in IQVIA by 0.8% in the third quarter. Principal Financial Group Inc. now owns 209,021 shares of the medical research company's stock valued at $49,532,000 after buying an additional 1,750 shares during the last quarter. Oddo BHF Asset Management Sas acquired a new position in IQVIA during the 3rd quarter valued at about $2,771,000. Franklin Resources Inc. increased its stake in shares of IQVIA by 1.2% in the third quarter. Franklin Resources Inc. now owns 501,807 shares of the medical research company's stock valued at $117,031,000 after purchasing an additional 6,011 shares during the period. Tidal Investments LLC raised its holdings in shares of IQVIA by 9.3% during the third quarter. Tidal Investments LLC now owns 5,980 shares of the medical research company's stock valued at $1,417,000 after buying an additional 509 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new position in shares of IQVIA during the third quarter worth approximately $2,310,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on IQV. TD Cowen cut their target price on IQVIA from $270.00 to $255.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of IQVIA from $270.00 to $265.00 and set a "buy" rating for the company in a report on Friday, November 1st. Redburn Atlantic began coverage on shares of IQVIA in a research report on Monday, October 14th. They set a "buy" rating and a $276.00 price target on the stock. The Goldman Sachs Group decreased their price objective on shares of IQVIA from $280.00 to $250.00 and set a "buy" rating for the company in a report on Friday, November 1st. Finally, Stephens began coverage on IQVIA in a research report on Friday, December 20th. They issued an "overweight" rating and a $250.00 target price for the company. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $255.82.

IQVIA Trading Down 0.4 %

Shares of NYSE:IQV traded down $0.86 during mid-day trading on Friday, hitting $199.39. The stock had a trading volume of 503,090 shares, compared to its average volume of 1,197,282. The company's 50 day moving average is $205.48 and its 200-day moving average is $222.72. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The company has a market cap of $36.19 billion, a PE ratio of 26.17, a P/E/G ratio of 2.05 and a beta of 1.49.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.